Gardner, MA - New England Peptide (NEP) and the Atlantic Cancer Research Institute (ACRI) have established an official partnership to develop peptide reagents that strongly bind to cancer-related proteins.
“These peptides will have multiple research applications across a wide range of cell lines and human tissues,” said Dr. Rodney Ouellette, ACRI’s CEO and Director of Discovery.
ACRI and NEP identified the peptides through a four-year research collaboration.
“We are very excited by the breakthrough potential for cancer diagnostics and eventually therapeutics,” said Scott Lewis, NEP’s Antibody Division Director. “The materials are still in the testing phase, but we anticipate that our research partnership will culminate in a series of commercial products.”
The research partnership consists of an ongoing exchange of ideas and research. NEP now provides technical expertise in peptide design, characterization and process feasibility through its PepCROTM suite of services.
“As an integrator of knowledge across the spectrum of all peptide uses, we are ideally suited to partner with ACRI,” said Dave Robinson, NEP’s CEO. “Our collaborative experience with ACRI is one of the relationships which led to the development of PepCROTM, NEP’s new contract-based R & D service.”
About Atlantic Cancer Research Institute (ACRI)
The Atlantic Cancer Research Institute (ACRI) is a non-profit organization founded in 1998 and housed at the Dr. Georges-L. Dumont Regional Hospital in Moncton, New Brunswick. Thanks to its unique expertise, the ACRI has become a true centre of excellence in cancer research. Scientists are working with partners in Canada and around the world to discover the genetic origins of cancer and pursuing three main areas of development: early screening; enhanced diagnosis, and targeted treatment. The multidisciplinary research team of approximately 35 people have expertise in genomics, proteomics, molecular biology, cell biology, immunology, bioinformatics, pathology, synthetic and organic chemistry, mass spectrometry as well in vitro and in vivo testing. Through its work, the ACRI is contributing to the global research effort aimed at combating cancer. More information can be found at www.atlanticcancer.ca .
About New England Peptide (NEP)
New England Peptide, founded in 1998, designs and produces custom peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. Headquartered in the Boston metro area in Gardner, Mass., the company’s chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications.
Peptides are small proteins that play key roles in biochemical regulation of all life systems, helping to fight diseases as diverse as cancer, diabetes, obesity and HIV/AIDS. Peptides’ inherent low toxicity and high potency, coupled with improved drug delivery methods and enhanced manufacturing capabilities, are fueling a surge in research and clinical use. More information can be found at www.newenglandpeptide.com.